Apnimed Q2: $125.9M Net Income Driven by One-Time Gains; Material Weakness in ICFR Disclosed
APMD sits 29% above its 52-week low of $22.35.
Summary
Apnimed reported Q2 2026 net income of $125.9 million driven by one-time gains from the SASS disposition and deposit liability reversal, while disclosing a material weakness in internal controls and a $150 million credit facility.
Key Events · Earnings and Guidance · APMD
-
Q2 Net Income $125.9M — All One-Time Gains
Net income of $125.9 million for Q2 2026 was driven by an $85.4 million gain on sale of the SASS equity method investment and a $57.1 million gain on reversal of a deposit liability. Operating loss was $11.7 million for the quarter.
-
Material Weakness in ICFR Disclosed
Management concluded disclosure controls and procedures were not effective as of June 30, 2026 due to a material weakness: ineffective control environment, insufficient IT controls, and lack of accounting personnel for complex transactions.
-
$150M Credit Facility with Revenue Interest
The April 2026 Credit Agreement provides up to $150 million in term loans. $50 million Tranche A was drawn, with warrants for 100,163 shares issued. The company must maintain a $20 million minimum cash balance in controlled accounts and pay a revenue interest on net sales.
-
Cash Runway Through Mid-2028
Cash and cash equivalents were $172.8 million as of June 30, 2026. Combined with $200.4 million net IPO proceeds, management expects funding through the middle of 2028.
Analysis · APMD · Life Sciences
Apnimed's Q2 2026 net income of $125.9 million is entirely non-operational — an $85.4 million gain on the SASS disposition and a $57.1 million gain on reversal of a deposit liability. The core business still lost money from operations. More importantly, the 10-Q discloses a material weakness in internal control over financial reporting that was not in the concurrent 8-K headline, and details a $150 million credit facility with revenue-interest obligations and a $20 million minimum cash collateral requirement. The company has $172.8 million in cash and runway through mid-2028, but the ICFR weakness and complex fair-value accounting for the credit facility and convertible notes raise financial-reporting risk.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APMD was trading at $28.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $22.35 to $35.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.